Bone marrow transplantation: how important is CD34 cell dose in HLA-identical stem cell transplantation?
A recent analysis of Fred Hutchinson Cancer Research Center data has been undertaken to investigate the association of infused CD34 cell dose with various clinical outcomes after HLA-identical transplantation. Separate assessments for unrelated vs related donors and the use of bone marrow or mobilized G-CSF stimulated peripheral blood mononuclear cells (G-PBMC) have been incorporated. The three primary findings are: (1) Higher CD34 dose results in better neutrophil and platelet recovery in all settings. (2) Higher CD34 doses (8 x 10(6)/kg) are associated with the development of more chronic graft-versus-host disease when using related G-PBMC. (3) Higher CD34 dose is correlated with improved survival after unrelated donor bone marrow transplantation. These data suggest that the CD34 content of a graft can have a significant impact on clinical outcome after allogeneic transplantation, but defining an optimal dose is dependent on both the type of donor and the stem cell source.
Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA.
S
S
Heimfeld
D018952:Antigens, CD34 / Q000502:physiology*; D016026:Bone Marrow Transplantation; D006086:Graft vs Host Disease / Q000401:mortality / Q000517:prevention & control; D006680:HLA Antigens / Q000276:immunology*; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans
D018952:Antigens, CD34; D006680:HLA Antigens